Specific efficacy of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced neuroendocrine tumours of the small intestine

Overview of attention for article published in European Journal of Nuclear Medicine and Molecular Imaging, March 2015

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (67th percentile)
Good Attention Score compared to outputs of the same age and source (73rd percentile)

Mentioned by

policy: 1 policy source

twitter: 1 X user

Citations

dimensions_citation: 91 Dimensions

Readers on

mendeley: 59 Mendeley

Summary Policy documents X Dimensions citations

So far, Altmetric has seen 2 policy documents that reference this research output.

Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours : Committee papers

Cited by National Institute for Health and Care Excellence on 10 Jul 2018

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease: Committee papers

Cited by National Institute for Health and Care Excellence on 05 May 2017

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.